Cardiovascular drug interactions.
Drug interactions may be responsible for certain changes in therapeutic response and toxicity of cardiac drugs. Interactions occur at the sites of drug absorption and elimination as well as at the receptor sites in the pacemaker cells, specialized conducting tissue, and myocardium. Studies of the kinetics of cardiac drugs are being applied clinically in an effort to reduce the danger of adverse drug interactions in heart patients.
D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001283:Atrioventricular Node / Q000503:physiopathology; D001682:Biological Availability; D003404:Creatinine / Q000378:metabolism; D004071:Digitalis Glycosides / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D004074:Digitoxin / Q000378:metabolism; D004077:Digoxin / Q000652:urine; D004347:Drug Interactions; D004562:Electrocardiography; D004721:Endoplasmic Reticulum; D006321:Heart / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D007700:Kinetics; D008099:Liver / Q000648:ultrastructure; D009638:Norepinephrine / Q000627:therapeutic use; D010656:Phenylephrine / Q000627:therapeutic use; D011863:Radioimmunoassay; D012770:Shock, Cardiogenic / Q000188:drug therapy; D013565:Sympatholytics / Q000494:pharmacology*; D013610:Tachycardia / Q000188:drug therapy
D000889:Anti-Arrhythmia Agents; D004071:Digitalis Glycosides; D013565:Sympatholytics; D010656:Phenylephrine; D004077:Digoxin; D003404:Creatinine; D004074:Digitoxin; D009638:Norepinephrine